Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deniz Can Guven

Showing results (31-40 of 134) with videos related to

Pageof 14
Sort By:
Critical Reviews in Oncology/Hematology|May 9, 2022
The efficacy of immune checkpoint inhibitors in rare tumors: A systematic review of published clinical trialsDeniz Can Guven, Bettzy Stephen, Taha Koray Sahin, et al.
Cancers|May 14, 2025
Treatment-Related Adverse Events in Extended Stage Small Cell Lung Cancer Patients Receiving First-Line Chemoimmunotherapy Versus Chemotherapy Alone: A Systematic Review and Meta-AnalysisElsa Vitale, Alessandro Rizzo, Lorenza Maistrello, et al.
Pharmaceuticals (Basel, Switzerland)|July 27, 2024
Prognostic Significance of Pan-Immune-Inflammation Value in Patients with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab EmtansineTaha Koray Sahin, Arif Akyildiz, Osman Talha Dogan, et al.
Expert Review of Anticancer Therapy|December 29, 2025
Elacestrant in metastatic breast cancer: current advancements and future perspectivesTaha Koray Sahin, Binura Makasheva, Deniz Can Guven, et al.
Heliyon|April 1, 2024
Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancerFrancesca Matilde Schipilliti, Denise Drittone, Federica Mazzuca, et al.
Critical Reviews in Oncology/Hematology|November 20, 2021
A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancerDeniz Can Guven, Taha Koray Sahin, Hasan Cagri Yildirim, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 11, 2023
Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient dataDeniz Can Guven, Enes Erul, Yunus Kaygusuz, et al.
Frontiers in Oncology|October 5, 2020
Perspectives, Knowledge, and Fears of Cancer Patients About COVID-19Deniz Can Guven, Taha Koray Sahin, Oktay Halit Aktepe, et al.
Expert Review of Anticancer Therapy|May 24, 2023
Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatmentDeniz Can Guven, Hasan Cagri Yildirim, Fatih Kus, et al.
Anti-Cancer Drugs|February 2, 2023
A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant metastatic pancreatic cancerHasan Cagri Yildirim, Rashad Ismayilov, Arif Akyildiz, et al.
Pageof 14

Showing results (31-40 of 134) with videos related to

Sort By:
Pageof 14
Critical Reviews in Oncology/Hematology|May 9, 2022
The efficacy of immune checkpoint inhibitors in rare tumors: A systematic review of published clinical trialsDeniz Can Guven, Bettzy Stephen, Taha Koray Sahin, et al.
Cancers|May 14, 2025
Treatment-Related Adverse Events in Extended Stage Small Cell Lung Cancer Patients Receiving First-Line Chemoimmunotherapy Versus Chemotherapy Alone: A Systematic Review and Meta-AnalysisElsa Vitale, Alessandro Rizzo, Lorenza Maistrello, et al.
Pharmaceuticals (Basel, Switzerland)|July 27, 2024
Prognostic Significance of Pan-Immune-Inflammation Value in Patients with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab EmtansineTaha Koray Sahin, Arif Akyildiz, Osman Talha Dogan, et al.
Expert Review of Anticancer Therapy|December 29, 2025
Elacestrant in metastatic breast cancer: current advancements and future perspectivesTaha Koray Sahin, Binura Makasheva, Deniz Can Guven, et al.
Heliyon|April 1, 2024
Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancerFrancesca Matilde Schipilliti, Denise Drittone, Federica Mazzuca, et al.
Critical Reviews in Oncology/Hematology|November 20, 2021
A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancerDeniz Can Guven, Taha Koray Sahin, Hasan Cagri Yildirim, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 11, 2023
Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient dataDeniz Can Guven, Enes Erul, Yunus Kaygusuz, et al.
Frontiers in Oncology|October 5, 2020
Perspectives, Knowledge, and Fears of Cancer Patients About COVID-19Deniz Can Guven, Taha Koray Sahin, Oktay Halit Aktepe, et al.
Expert Review of Anticancer Therapy|May 24, 2023
Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatmentDeniz Can Guven, Hasan Cagri Yildirim, Fatih Kus, et al.
Anti-Cancer Drugs|February 2, 2023
A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant metastatic pancreatic cancerHasan Cagri Yildirim, Rashad Ismayilov, Arif Akyildiz, et al.
Pageof 14